Doc logic, one thing that stands out here is that even without pulling up any filing, it would not make sense to validate an automated closed system like EDEN and then confine its use only to DCVax-L while keeping DCVax-Direct on a legacy workflow. The biology and the engineering make that almost impossible.
The NYAS presentation from Dr. Marnix Bosch actually makes this very clear. On page 3 of the deck he defines DCVax-Direct as autologous unloaded partially activated dendritic cells for intratumoral injection, and the slide explicitly states that DCVax-Direct “is manufactured in a closed and automated system that is specifically designed to maximize therapeutic effects.”
That is not my interpretation.That is Bosch’s literal wording.
The description is exactly what EDEN is. The deck lists properties that match the EDEN platform precisely:
• uniformly immature dendritic cells
• tightly controlled partial maturation
• controlled activation sequence
• predictable cytokine production
• designed for manufacturing at scale
These are EDEN characteristics.And Bosch is applying them directly to DCVax-Direct.
He does not show DCVax-L anywhere in this technical section.He uses Direct as the prototype for the next generation architecture.
The rest of the NYAS deck reinforces the same point. Every cytokine amplification graph, every booster combination, and every maturation pattern is shown in the context of intratumoral DCVax-Direct cells. The booster logic he presents only works if the dendritic cells are created in a reproducible automated system. Those combinations cannot safely sit on top of an old semi open manual process. They require the uniformity you only get from EDEN.
Now add what the 10Q actually says. It describes the full EDEN validation sequence:
• the choice between TFF and the commercial system
• transfer into Grade C cleanrooms
• validation of all equipment after installation
• operator aseptic simulations
• three consecutive PQQ runs at scale
None of this would be necessary if DCVax-Direct were already being manufactured in a modern closed system. A sponsor never repeats the entire qualification cycle unless the platform is new to the IND.
On top of that, the filing states that the manufacturing and product related portions of the new DCVax-Direct IND are complete. That is only possible if the system that will be used for the trial is already validated. The only system described anywhere in the filing that fits that profile is EDEN.
So even before looking at filings, logic alone tells you that the next generation Direct program, which depends on booster agents, maturation tuning, immune conditioning, and complex intratumoral biology, cannot be run on an outdated partially manual workflow. Bosch’s presentation confirms that the future of Direct requires a closed automated system, and the company’s own 10Q describes the exact EDEN validation steps.
If you recall a filing that states EDEN would not be used for DCVax-Direct, it would be helpful to bring it forward. Everything in the official documents, including Bosch’s slides, points in the opposite direction.
Bullish
Market Data 
Markets 
AI
